Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
ka2507 (2 trials)
ka2237 (1 trial)
Biliary Tract Neoplasms (Phase 2)
Lymphoma (Phase 1)
Lymphoma, B-Cell (Phase 1)
Neoplasms (Phase 1)
Trials (3 total)
Trial APIs (2 total)